[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
13-Dec-2010

[ | E-mail ] Share Share

Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
@jclinicalinvest

New approaches needed for treating chronic myeloid leukemia

Chronic myeloid leukemia (CML) was transformed from a fatal disease to a chronic condition by the development of a drug known as imatinib, which targets the protein that drives this disease (BCR-ABL). However, imatinib does not cure patients, they must take the drug lifelong, as disease recurs if they stop taking it. This is because imatinib does not kill all the CML cells; some, which are known as CML stem cells, persist. A key to therapeutically targeting CML stem cells is knowing whether they rely on BCR-ABL to persist. Answers to this will determine whether more effective BCR-ABL inhibitors are likely to be effective treatments or whether new approaches to targeting these cells need to be developed.

A team of researchers, led by Brian Drucker and Michael Deininger, at Oregon Health and Science University, Portland, has now shown clearly that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy. As noted by the authors and, in an accompany commentary, Alexander Perl and Martin Carroll, at the University of Pennsylvania, Philadelphia, the data indicate that therapeutics targeting BCR-ABL will not improve CML treatment and that new approaches are needed if further advances in patient care are to be made.

###

TITLE: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

AUTHOR CONTACT:
Michael W. Deininger
Oregon Health and Science University, Portland, Oregon, USA.
Phone: 503.494.1091; Fax: 503.494.3688; E-mail: deinginge@ohsu.edu.

Brian J. Druker,
Oregon Health and Science University, Portland, Oregon, USA.
Phone: 503.494.1288; Fax: 503.494.3688; E-mail: drukerb@ohsu.edu.

View this article at: http://www.jci.org/articles/view/35721?key=1602b640084adb5cfcdc

ACCOMPANYING COMMENTARY
TITLE: BCR-ABL kinase is dead; long live the CML stem cell

AUTHOR CONTACT:
Martin Carroll
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Phone: 215.573.5217; Fax: 215.573.7049; E-mail: carroll2@mail.med.upenn.edu.

View this article at: http://www.jci.org/articles/view/43605?key=1da0d8726712d0c91c88



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.